Operating cash flow was -$10.6M and free cash flow was -$15.8M in Q3 2026, with a free cash flow margin of -12.9% that remains firmly negative, and no dividends or buybacks were recorded, so capital is being consumed rather than returned.
GeneDx Holdings Corp. (WGS) cash flow statement — 6-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 |
|---|
| Cash from Operations | -75.08M | 33.28M | -28.5M | -180.15M | -319.15M | -190.43M | -93.13M |
| Operating CF Margin % | - | 7.78% | -9.33% | -88.93% | -135.99% | -89.74% | -51.93% |
| Operating CF Growth % | -960.72% | 216.78% | 84.18% | 43.55% | -67.59% | -104.49% | - |
| Net Income | -111.05M | -21.02M | -52.29M | -175.77M | -548.98M | -245.39M | -241.34M |
| Depreciation & Amortization | 27.3M | 25.22M | 21.95M | 33.73M | 59.31M | 21.81M | 11.73M |
| Stock-Based Compensation | 33.37M | 32.16M | 9.14M | -326K | 41.98M | 219.42M | 120.23M |
| Deferred Taxes | -43K | 0 | -343K | -926K | -49.12M | 0 | 0 |
| Other Non-Cash Items | 35.78M | 12.51M | 17.79M | 1.38M | 141.53M | -194.35M | 2.4M |
| Working Capital Changes | -60.44M | -15.6M | -24.75M | -38.24M | 36.13M | 8.08M | 13.85M |
| Change in Receivables | -31.41M | -36.23M | -5.42M | 10.26M | 5.53M | 5.54M | -10.61M |
| Change in Inventory | -11.19M | -3.44M | -2.58M | 975K | 4.6M | -10.62M | -8.98M |
| Change in Payables | -12.39M | 12.1M | -20.46M | -46.95M | 34.46M | 0 | 0 |
| Cash from Investing | -41.38M | -61.52M | -30.13M | -43.73M | -141.33M | -20.79M | -31.97M |
| Capital Expenditures | -26.14M | -19.02M | -5.49M | -5.71M | -14.32M | -9.4M | -24.09M |
| CapEx % of Revenue | 5.67% | 4.45% | 1.8% | 2.82% | 6.1% | 4.43% | 13.44% |
| Acquisitions | -32.86M | -32.86M | 0 | -8.11M | -127M | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 33.2M | 0 | 0 | 0 | 0 | -11.39M | -7.88M |
| Cash from Financing | 116.63M | 48.02M | 44.16M | 186.24M | 197.31M | 493.73M | 129.06M |
| Debt Issued (Net) | 89.09M | -3.66M | -3.23M | 42.95M | -3.29M | -13.47M | 11.73M |
| Equity Issued (Net) | -20.24M | 51.69M | 46.5M | 143M | 197.66M | 442.68M | 117.32M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 47.78M | 0 | 891K | 285K | 2.95M | 64.51M | 0 |
| Net Change in Cash | 174K | 19.79M | -14.47M | -37.72M | -263.17M | 282.51M | 3.95M |
| Free Cash Flow | -101.22M | 14.26M | -33.99M | -185.86M | -333.48M | -211.22M | -125.1M |
| FCF Margin % | -21.97% | 3.34% | -11.13% | -91.75% | -142.09% | -99.54% | -69.76% |
| FCF Growth % | -754.44% | 141.96% | 81.71% | 44.27% | -57.88% | -68.84% | - |
| FCF per Share | -3.39 | 0.53 | -1.26 | -7.64 | -32.58 | -64.49 | -22.23 |
| FCF Conversion (FCF/Net Income) | 0.91x | -1.58x | 0.55x | 1.02x | 0.58x | 0.78x | 0.39x |
| Interest Paid | -222K | 6.41M | 6.68M | 3.04M | 1.93M | 2.75M | 1.75M |
| Taxes Paid | -112K | 1.27M | 1.17M | 1.47M | 1.24M | 349K | 0 |
Quick answers to the most common questions about buying WGS stock.
GeneDx Holdings Corp. (WGS) generated $33.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
GeneDx Holdings Corp. (WGS) generated $14.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
GeneDx Holdings Corp. (WGS) spent $19.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Operating Cash Flow Tracks Losses Inconsistently
Based on reported quarterly figures, WGS posted a Q1 2026 net loss of -$63.3M against operating cash outflow of -$32.4M, yielding an OCF-to-net-income ratio of 0.51 that suggests non-cash charges absorbed part of the loss.
The gap between net income and operating cash flow is the central signal in this dataset, and it fluctuates sharply, with ratios ranging from 0.15 to over 1.6 across recent quarters. Such instability suggests that earnings are heavily influenced by non-cash and timing items rather than steady cash generation. Investors should monitor whether the positive ratio in Q3 2026 reflects genuine conversion improvement or merely a temporary working capital reversal.
Free Cash Flow Remains Deeply Negative
As reported in the cash flow statements, WGS's free cash flow margin reached -38.0% in Q1 2026 and -34.2% in Q2 2026, with only a modest improvement to -12.9% in Q3 2026 that remains firmly negative.
Free cash flow has been negative in most recent periods, with only brief positive stretches in 2025 that were not sustained. The latest quarter's narrower burn appears encouraging, but it still sits well below breakeven and does not yet demonstrate a durable turn. The trajectory warrants further investigation to determine whether margin repair can outpace continued working capital drag.
Working Capital Drag Drives Cash Volatility
Based on reported figures, working capital absorbed roughly -$23.2M in Q1 2026 and -$22.6M in Q2 2026, indicating that receivables and timing effects contributed materially to operating cash outflows during the period.
Working capital swings appear to be a dominant driver of quarterly operating cash flow, often exceeding the magnitude of underlying operating results. This pattern is consistent with revenue recognition dynamics such as implicit price concessions and prior-period true-ups noted in the business profile, which may delay cash collection from payers. Investors should monitor collection cycles, as sustained working capital consumption could keep cash needs elevated even if reported revenue continues to grow.
Light Capital Intensity Limits Investment Burden
According to quarterly disclosures, WGS's capital expenditures ran between 0.8% and 8.8% of revenue over the period, with the Q2 2026 peak of -$10.1M representing the most significant infrastructure outlay.
Capital spending is modest relative to revenue, suggesting the laboratory footprint does not currently demand heavy reinvestment. The fluctuation in capex intensity may reflect lumpy equipment purchases rather than a steady maintenance baseline. Because the company is not yet cash-flow positive, even this moderate spending adds to the funding need, and the mix between maintenance and growth capex remains undisclosed in the supplied data.
No Shareholder Returns Amid Cash Burn
Based on reported figures, WGS recorded no dividends or share repurchases across all ten quarters, with acquisition outflows appearing only once at -$32.9M in Q4 2025, indicating capital has been retained rather than returned.
The absence of distributions is consistent with a company still funding operating losses and working capital needs from its existing liquidity base. The single acquisition-related outflow in late 2025 coincides with the restructuring period described in the business profile and warrants scrutiny of its strategic purpose. Investors should monitor whether future cash deployment prioritizes balance sheet preservation or renewed investment in the data platform.
Cash Burn Masked by Non-Cash Add-Backs
Based on reported figures, stock-based compensation of $8.3M in Q3 2026 and $6.3M in Q2 2026 is a non-cash add-back that may flatter reported operating cash flow, warranting adjustment before judging the true cash burn rate.
Because SBC is excluded from operating cash outflows, the headline OCF figures overstate economic cash generation to the extent equity compensation substitutes for cash wages. The quarterly D&A of roughly $6.5M to $7.0M also cushions reported operating results without reflecting any replacement capital required for the laboratory asset base. Investors should monitor whether the Q3 2026 improvement is sustained once these non-cash items and the implied fourth-quarter guidance step-up are scrutinized.